- Alpha-1 Antitrypsin Deficiency Disease Market Research Report 2025, Competitive Analysis of Shire, GSK, CSL Behring, AstraZeneca, Grifols, Teva Pharma, Boehringer Ingelheim, Kamada, Pfizer, Baxter
Nov 11, 2025
Company Logo
The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market.
Alpha-1 Antitrypsin Deficiency Disease MarketAlpha-1 Antitrypsin Deficiency Disease Market
Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Deficiency Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.
The Alpha-1 Antitrypsin Deficiency Disease Market was valued at USD 2.24 Billion in 2024, and is expected to reach USD 3.53 Billion by 2030, rising at a CAGR of 7.82%
Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency in the alpha-1 antitrypsin protein, which leads to a higher risk of developing lung and liver diseases. While Alpha-1 Antitrypsin Deficiency Disease is considered a rare disease, its impact on patients' quality of life and healthcare systems is significant.
As research advances and awareness grows, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing transformations, offering both challenges and opportunities. Alpha-1 antitrypsin is a protein produced by the liver that plays a crucial role in protecting the lungs from damage caused by enzymes released during inflammation. In individuals with Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to the production of a misfolded protein that accumulates in the liver rather than being released into the bloodstream. This deficiency results in a higher susceptibility to lung diseases like chronic obstructive pulmonary disease (COPD) and liver diseases like cirrhosis.
The Alpha-1 Antitrypsin Deficiency Disease market is relatively small due to the rare nature of the disease. However, it is gaining attention from researchers, pharmaceutical companies, and healthcare providers. The market is characterized by a few key players specializing in diagnostics, treatments, and therapies. These companies focus on developing therapies that aim to address the underlying deficiency and manage associated complications. Advancements in biotechnology, genomics, and personalized medicine have enabled the development of more targeted and effective therapies for Alpha-1 Antitrypsin Deficiency Disease.
These innovations have the potential to revolutionize treatment approaches, leading to better patient outcomes and improved quality of life. Government initiatives and increased research funding have played a pivotal role in driving the growth of the global Alpha-1 Antitrypsin Deficiency Disease market. As awareness about rare diseases like Alpha-1 Antitrypsin Deficiency Disease increases, governments and regulatory bodies are introducing policies and programs to support research, diagnosis, and treatment development for such conditions. Funding for research projects, clinical trials, and patient support programs have attracted the attention of pharmaceutical companies and researchers, leading to accelerated advancements in the field.
Key Market Drivers
Story Continues
Growing Patient Population
Alpha-1 Antitrypsin Deficiency (AATD) is a rare but serious genetic disorder that impairs lung and liver function, primarily due to insufficient levels of the alpha-1 antitrypsin protein. Though historically underdiagnosed, awareness surrounding AATD is steadily increasing. According to the Alpha-1 Foundation, it is estimated that 1 in 2,500 individuals in the United States may have the condition, but only a fraction have been properly diagnosed. This growing recognition is leading to a larger identified patient pool, highlighting the urgent need for improved diagnostic infrastructure and targeted therapies to manage and treat the condition effectively.
Misdiagnosis remains a significant hurdle in the clinical journey of many AATD patients. Because symptoms such as shortness of breath and wheezing overlap with more common conditions like asthma or chronic obstructive pulmonary disease (COPD), proper diagnosis is often delayed. However, with the rollout of improved diagnostic tools and broader genetic testing programs, correct identification is becoming more feasible. A 2023 study indicated that over 60% of newly confirmed AATD cases were initially misdiagnosed, underscoring the critical importance of awareness campaigns and early screening initiatives in catching the disease sooner and enabling timely treatment interventions.
As the pool of diagnosed patients expands, so does the interest from pharmaceutical companies and researchers to develop targeted treatments. Enzyme replacement therapies (ERTs), which replenish the deficient alpha-1 antitrypsin protein, have become a cornerstone in managing AATD. These therapies help reduce lung inflammation and preserve respiratory function. At the same time, advancements in gene therapy and RNA-based treatments are providing hope for long-term or even curative solutions. The clinical pipeline is expanding rapidly, with a number of therapies in various stages of development, targeting both symptomatic relief and genetic correction.
The availability of multiple therapeutic options is not only enhancing patient care but also creating new opportunities in the healthcare market. This is especially true as physicians are becoming more equipped to tailor treatments to the severity and progression of the disease. Increasing participation in patient registries and real-world evidence collection are further contributing to a deeper understanding of AATD and enabling personalized medicine approaches. As more individuals are diagnosed and gain access to effective care, the growing patient population will continue to be a central driver in the advancement of the Alpha-1 Antitrypsin Deficiency Disease treatment landscape.
Key Market Challenges
Under diagnosis and Misdiagnosis
One of the most pressing challenges in the Alpha-1 Antitrypsin Deficiency (AATD) market is the high rate of underdiagnosis. Due to the rarity of the condition and low awareness among both patients and primary care providers, AATD often goes undetected for years. Many individuals remain asymptomatic until the disease has significantly progressed, making early intervention difficult. Even when symptoms appear such as shortness of breath or recurrent respiratory infections - they are frequently attributed to more common conditions like asthma or chronic obstructive pulmonary disease (COPD). This diagnostic delay not only worsens patient outcomes but also limits the window of opportunity for implementing effective treatments and managing disease progression proactively.
Misdiagnosis compounds the challenge, as individuals with AATD are often treated incorrectly for unrelated respiratory or liver conditions. These inappropriate treatments can lead to ineffective care, increased healthcare costs, and a delay in addressing the root genetic cause of the symptoms. For example, corticosteroids may be prescribed under the assumption of asthma, when in fact, AATD-related lung damage requires enzyme replacement or targeted therapy.
Moreover, many clinicians lack familiarity with the specific diagnostic tests needed such as serum AAT levels and genetic testing - leading to oversight in patient evaluation. This systemic issue highlights the need for increased physician education, standardized screening protocols, and public awareness campaigns to ensure timely, accurate diagnosis and improve long-term patient care.
Key Market Trends
Technological Advancements
Technological strides in genetic screening have enabled early detection of Alpha-1 Antitrypsin Deficiency Disease. Genetic tests can identify specific mutations associated with the deficiency, allowing healthcare providers to diagnose individuals even before symptoms manifest. This proactive approach empowers patients to make informed decisions about their health and lifestyle, potentially mitigating the severity of complications. Further, the advent of precision medicine, which tailors treatment plans based on an individual's genetic makeup, is revolutionizing Alpha-1 Antitrypsin Deficiency Disease management.
With insights gleaned from genetic testing, medical professionals can design personalized interventions, optimizing treatment efficacy and minimizing adverse effects. The emergence of gene therapy and gene editing technologies is creating exciting avenues for treating genetic disorders like Alpha-1 Antitrypsin Deficiency Disease. Researchers are exploring ways to replace or correct the mutated gene responsible for Alpha-1 Antitrypsin Deficiency Disease, potentially restoring normal protein production. These innovative approaches hold the promise of not just managing the symptoms but addressing the root cause of the condition. Telemedicine has become an essential tool in managing chronic diseases.
Patients with Alpha-1 Antitrypsin Deficiency Disease can now access remote consultations with specialists, receive real-time guidance, and monitor their health using wearable devices. This facilitates regular check-ins and timely interventions, ultimately enhancing the overall quality of care. As the technological landscape continues to evolve, the prospects for individuals with Alpha-1 Antitrypsin Deficiency are looking increasingly optimistic. Innovative therapies, precise diagnostics, and personalized treatment plans are reshaping the Alpha-1 Antitrypsin Deficiency Disease landscape, offering renewed hope to patients and their families.
However, challenges such as ethical considerations, accessibility, and cost-effectiveness must also be addressed to ensure that the benefits of these technological advancements are equitably distributed. The application of big data analytics and artificial intelligence (AI) in medical research has expedited the identification of potential drug candidates. AI algorithms can analyze massive datasets to pinpoint molecules that could modulate AAT production or function, expediting the drug discovery process.
Key Attributes:
Report Attribute Details No. of Pages 165 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.24 Billion Forecasted Market Value (USD) by 2030 $3.53 Billion Compound Annual Growth Rate 7.8% Regions Covered Global
Report Scope:
Key Market Players
Shire plc GlaxoSmithKline plc CSL Behring AstraZeneca Plc. Grifols S.A. Teva Pharmaceutical Industries Boehringer Ingelheim International GmbH Kamada Pharmaceuticals Pfizer Inc. Baxter International Inc.
Alpha-1 Antitrypsin Deficiency Disease Market, By Product:
Alpha-1 Proteinase Inhibitor Bronchodilato Corticosteroid Oxygen Therapy
Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:
Injection Oral Inhalation
Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:
Hospitals Pharmacy Retail Pharmacies Online Pharmacies
Alpha-1 Antitrypsin Deficiency Disease Market, By Region:
North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE
For more information about this report visit https://www.researchandmarkets.com/r/z6pcwy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Alpha-1 Antitrypsin Deficiency Disease Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments
- Countdown to Kamada (KMDA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Nov 6, 2025
Wall Street analysts expect Kamada (KMDA) to post quarterly earnings of $0.10 per share in its upcoming report, which indicates a year-over-year increase of 42.9%. Revenues are expected to be $46.25 million, up 10.8% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Kamada metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Distribution' will reach $5.45 million. The estimate suggests a change of +18.1% year over year.
Analysts' assessment points toward 'Revenues- Proprietary products' reaching $40.80 million. The estimate suggests a change of +9.9% year over year.
The combined assessment of analysts suggests that 'Gross Profit- Proprietary products' will likely reach $18.81 million. The estimate compares to the year-ago value of $16.26 million.
View all Key Company Metrics for Kamada here>>>
Over the past month, shares of Kamada have returned +1% versus the Zacks S&P 500 composite's +1.3% change. Currently, KMDA carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- KMDA vs. NVZMY: Which Stock Is the Better Value Option?
Oct 31, 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Currently, Kamada has a Zacks Rank of #2 (Buy), while Novozymes A/S has a Zacks Rank of #3 (Hold). This means that KMDA's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
KMDA currently has a forward P/E ratio of 17.34, while NVZMY has a forward P/E of 25.80. We also note that KMDA has a PEG ratio of 0.69. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. NVZMY currently has a PEG ratio of 1.16.
Another notable valuation metric for KMDA is its P/B ratio of 1.51. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, NVZMY has a P/B of 2.32.
These metrics, and several others, help KMDA earn a Value grade of A, while NVZMY has been given a Value grade of D.
KMDA is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that KMDA is likely the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
Novozymes A/S (NVZMY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- KMDA or ILMN: Which Is the Better Value Stock Right Now?
Oct 15, 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, Kamada is sporting a Zacks Rank of #2 (Buy), while Illumina has a Zacks Rank of #3 (Hold). This means that KMDA's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
KMDA currently has a forward P/E ratio of 17.34, while ILMN has a forward P/E of 20.20. We also note that KMDA has a PEG ratio of 0.69. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. ILMN currently has a PEG ratio of 2.19.
Another notable valuation metric for KMDA is its P/B ratio of 1.51. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ILMN has a P/B of 6.19.
These metrics, and several others, help KMDA earn a Value grade of A, while ILMN has been given a Value grade of C.
KMDA stands above ILMN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that KMDA is the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- KMDA vs. ILMN: Which Stock Is the Better Value Option?
Sep 29, 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Currently, Kamada has a Zacks Rank of #2 (Buy), while Illumina has a Zacks Rank of #3 (Hold). This means that KMDA's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
KMDA currently has a forward P/E ratio of 17.71, while ILMN has a forward P/E of 20.75. We also note that KMDA has a PEG ratio of 0.71. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ILMN currently has a PEG ratio of 2.25.
Another notable valuation metric for KMDA is its P/B ratio of 1.48. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, ILMN has a P/B of 6.24.
These metrics, and several others, help KMDA earn a Value grade of A, while ILMN has been given a Value grade of C.
KMDA stands above ILMN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that KMDA is the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- KMDA or ARGX: Which Is the Better Value Stock Right Now?
Sep 1, 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Kamada (KMDA) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Kamada has a Zacks Rank of #2 (Buy), while argenex SE has a Zacks Rank of #3 (Hold) right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that KMDA is likely seeing its earnings outlook improve to a greater extent. However, value investors will care about much more than just this.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
KMDA currently has a forward P/E ratio of 18.37, while ARGX has a forward P/E of 45.14. We also note that KMDA has a PEG ratio of 0.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ARGX currently has a PEG ratio of 0.83.
Another notable valuation metric for KMDA is its P/B ratio of 1.53. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, ARGX has a P/B of 7.15.
These metrics, and several others, help KMDA earn a Value grade of A, while ARGX has been given a Value grade of C.
KMDA has seen stronger estimate revision activity and sports more attractive valuation metrics than ARGX, so it seems like value investors will conclude that KMDA is the superior option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
argenex SE (ARGX) : Free Stock Analysis Report
Story Continues
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- KMDA vs. ILMN: Which Stock Is the Better Value Option?
Aug 14, 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Kamada and Illumina are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that KMDA is likely seeing its earnings outlook improve to a greater extent. However, value investors will care about much more than just this.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
KMDA currently has a forward P/E ratio of 21.09, while ILMN has a forward P/E of 22.89. We also note that KMDA has a PEG ratio of 0.84. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ILMN currently has a PEG ratio of 2.32.
Another notable valuation metric for KMDA is its P/B ratio of 1.68. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ILMN has a P/B of 6.88.
These metrics, and several others, help KMDA earn a Value grade of A, while ILMN has been given a Value grade of C.
KMDA stands above ILMN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that KMDA is the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
Story Continues
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- KMDA or ACAD: Which Is the Better Value Stock Right Now?
Jul 4, 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Kamada and Acadia Pharmaceuticals are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that KMDA has an improving earnings outlook. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
KMDA currently has a forward P/E ratio of 23.88, while ACAD has a forward P/E of 42.40. We also note that KMDA has a PEG ratio of 0.96. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ACAD currently has a PEG ratio of 4.51.
Another notable valuation metric for KMDA is its P/B ratio of 1.8. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ACAD has a P/B of 4.58.
Based on these metrics and many more, KMDA holds a Value grade of A, while ACAD has a Value grade of C.
KMDA stands above ACAD thanks to its solid earnings outlook, and based on these valuation figures, we also feel that KMDA is the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Strength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength?
Jun 25, 2025
Kamada (KMDA) shares rallied 9.5% in the last trading session to close at $7.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 9.5% gain over the past four weeks.
The sudden price rise can be attributed to growing investor optimism related to Kamada’s leadership in the field of specialty plasma-derived therapies and its portfolio of marketed products indicated for rare and serious conditions. Last month, the company reported robust financial results for the first quarter of 2025.
High Yield Savings Offers
Earn 4.10% APY** on balances of $5,000 or more View Offer
Earn up to 4.00% APY with Savings Pods View Offer
Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer
Powered by Money.com - Yahoo may earn commission from the links above.
This biopharmaceutical is expected to post quarterly earnings of $0.09 per share in its upcoming report, which represents a year-over-year change of +12.5%. Revenues are expected to be $45.06 million, up 6.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Kamada, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KMDA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Kamada belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Immunocore Holdings PLC Sponsored ADR (IMCR), closed the last trading session 2.9% higher at $32.01. Over the past month, IMCR has returned -0.1%.
Immunocore's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.24. Compared to the company's year-ago EPS, this represents a change of -4.4%. Immunocore currently boasts a Zacks Rank of #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?
May 28, 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Currently, Kamada has a Zacks Rank of #2 (Buy), while CSL Limited Sponsored ADR has a Zacks Rank of #4 (Sell). Investors should feel comfortable knowing that KMDA likely has seen a stronger improvement to its earnings outlook than CSLLY has recently. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
KMDA currently has a forward P/E ratio of 22.98, while CSLLY has a forward P/E of 24.59. We also note that KMDA has a PEG ratio of 0.92. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CSLLY currently has a PEG ratio of 1.96.
Another notable valuation metric for KMDA is its P/B ratio of 1.59. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, CSLLY has a P/B of 4.02.
Based on these metrics and many more, KMDA holds a Value grade of A, while CSLLY has a Value grade of D.
KMDA stands above CSLLY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that KMDA is the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
CSL Limited Sponsored ADR (CSLLY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
